Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

Lakshmikanth Katragadda, MD, Lindsay McCullough, MD, Yunfeng Dai, PhD, Jack W Hsu, MD, John W Hiemenz, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Maxim Norkin, MD PhD, Randy A Brown, MD, John R. Wingard, MD, Myron Chang, PhD, Jan S Moreb, MD

Blood (2015) 126 (23): 1988.

https://doi.org/10.1182/blood.V126.23.1988.1988

Published: 2015

Journal Articles

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Maxim Norkin, MD PhD, Myron Chang, PhD, An Qi, PhD, Helen Leather, BPharm, Lakshmikanth Katragadda, MD, Ying Li, MD PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Randy A. Brown, MD, Jack W. Hsu, MD, John W Hiemenz, MD, John R Wingard, MD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 3852.

https://doi.org/10.1182/blood.V126.23.3852.3852

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Lakshmikanth Katragadda, MD, Maxim Norkin, MD PhD, Myron Chang, PhD, Yunfeng Dai, PhD, Jan S Moreb, MD, W. Stratford May, MD PhD, Christopher R. Cogle, MD, Helen Leather, BPharm, Ying Li, MD PhD, Lamis K Eldjerou, MD, John W Hiemenz, MD, Randy A. Brown, MD, John R. Wingard, MD

Blood (2015) 126 (23): 3221.

https://doi.org/10.1182/blood.V126.23.3221.3221

Published: 2015

Journal Articles

Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome

Cindy Medina, B.S., Leylah Drusbosky, BS, Myron Chang, PhD, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, Mikkael A. Sekeres, MD MS, Mar Mallo, PhD, Francesc Sole, PhD, Rafael Bejar, MDPhD, Christopher R. Cogle, MD

Blood (2015) 126 (23): 96.

https://doi.org/10.1182/blood.V126.23.96.96

Published: 2015

Journal Articles

High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971

Minnie Abromowitch, MD, Amanda Termuhlen, MD, Myron Chang, PhD, Sherrie L. Perkins, MD, PhD, Thomas Gross, MD, PhD, Howard J. Weinstein, MD, Jonathan Finlay, MD

Blood (2008) 112 (11): 3610.

https://doi.org/10.1182/blood.V112.11.3610.3610

Published: 2008

Journal Articles

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

Patrick Brown, MD, Emily McIntyre, Rachel Rau, MD, Todd A. Alonzo, PhD, Robert Gerbing, MA, Soheil Meshinchi, MD PhD, Norman Lacayo, MD, Myron Chang, PhD, Robert Arceci, MD PhD, Donald Small, MD PhD

Blood (2006) 108 (11): 221.

https://doi.org/10.1182/blood.V108.11.221.221

Published: 2006

Journal Articles

Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study.

Martin A. Champagne, MD, Cecilia Fu, MD PhD, Myron Chang, PhD, Linda Cooley, PhD, Nyla A. Heerema, PhD, Charlotte Wood, CRA, Mary Ellen French, RN, Franklin O. Smith, MD, Mark L. Bernstein, MD

Blood (2006) 108 (11): 2140.

https://doi.org/10.1182/blood.V108.11.2140.2140

Published: 2006

Journal Articles

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Norman Lacayo, MD, Soheil Meshinchi, MD, Susana Raimondi, PhD, Chitra Saraiya, MS, Maureen O’Brien, MD, Ronald Yu, PhD, Dejan Juric, MD, Myron Chang, PhD, Cheryl Willman, MD, Robert Tibshirani, PhD, Yaddanapudi Ravindranath, MD, Branimir Sikic, MD, Howard Weinstein, MD, Gary Van Houten Dahl, MD

Blood (2005) 106 (11): 2372.

https://doi.org/10.1182/blood.V106.11.2372.2372

Published: 2005

Journal Articles

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Robert P. Castleberry, MD, Mignon L. Loh, MD, Nalini Jayaprakash, April Peterson, Vicky Casey, Myron Chang, PhD, Brigitte Widemann, MD, Peter D. Emanuel, MD

Blood (2005) 106 (11): 2587.

https://doi.org/10.1182/blood.V106.11.2587.2587

Published: 2005

Journal Articles

Safety and Efficacy of CBV Followed by Autologous PBSC Transplant in Children with Lymphoma after Failed Induction or First Relapse - a Children’s Oncology Group Study.

Richard E. Harris, MD, Erin Morris, RN, Phyllis Warkentin, MD, Adrianna Vlachos, MD, Myron Chang, PhD, Mitchell S. Cairo, MD

Blood (2004) 104 (11): 899.

https://doi.org/10.1182/blood.V104.11.899.899

Published: 2004

Journal Articles

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred G. Behm, MD, Myron Chang, PhD, Howard Weinstein, MD

Blood (2004) 104 (11): 616.

https://doi.org/10.1182/blood.V104.11.616.616

Published: 2004

NARROW

Effect of Melphalan 140 Mg/m 2 Versus 200 Mg/m 2 on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation

A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy

Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes

Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome

High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study.

Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

Safety and Efficacy of CBV Followed by Autologous PBSC Transplant in Children with Lymphoma after Failed Induction or First Relapse - a Children’s Oncology Group Study.

Genetic Randomization to Allogeneic Bone Marrow Transplant in First Remission Pediatric Acute Myeloid Leukemia Patients, Pediatric Oncology Group 9421 (Now Childrens Oncology Group).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only